Bioinformatics identification of miR-514b-5p promotes NSCLC progression and induces PI3K/AKT and p38 pathways by targeting small glutamine-rich tetratricopeptide repeat-containing protein beta
机构:[1]Department of Traditional Chinese Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, 510280, Guangdong, China.南方医科大学珠江医院[2]Department of VIP Region, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, China.
Lung cancer is the most aggressive cancer with the highest mortality and incidence rates worldwide. microRNAs have been identified as potential targets for non-small cell lung cancer (NSCLC) treatment. However, the modulatory role of miR-514b-5p in NSCLC progression is little known. Herein, miRNA expression datasets for NSCLC were downloaded from the Cancer Genome Atlas and Gene Ontology Omnibus databases. Gene expression was assessed using qRT-PCR, and western blot analysis, and immunohistochemical (IHC) staining was used to determine protein expression. Gain and loss of function experiments were performed to investigate the impact of miR-514b-5p and small glutamine-rich tetratricopeptide repeat-containing protein beta (SGTB) on cell proliferation and apoptosis. RNA immunoprecipitation (RIP) and dual-luciferase assays were performed to analyze the target gene of miR-514b-5p. The biological roles of miR-514b-5p were lastly evaluated using nude mouse tumorigenicity assays in vivo. We found that miR-514b-5p was dramatically increased in NSCLC tissues and higher miR-514b-5p expression was associated with poorer overall survival in NSCLC patients. Furthermore, overexpression of miR-514b-5p promoted NSCLC cell growth and suppressed apoptosis by inducing the activation of the PI3K/AKT and p38 signaling pathways. Mechanistically, dual-luciferase and RIP results highlighted that SGTB was a target gene of miR-514b-5p. Moreover, overexpression of SGTB reduced cell division and promoted apoptosis in vitro through blocking the PI3K/AKT and p38 signaling pathways. Our findings indicated that miR-514b-5p contributes to carcinoma progression in NSCLC via the PI3K/AKT and p38 signaling pathways by targeting SGTB and this could be a promising diagnostic and therapeutic target for the treatment of NSCLC.This article is protected by copyright. All rights reserved.
基金:
The research is supported by grants from National Natural Science Foundation of China (No. 82074159,
81874381) and Natural Science Foundation of Guangdong Province of China (No. 2021A1515011611,
2021A1515010491).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类|2 区生物学
小类|3 区生化与分子生物学
最新[2025]版:
大类|2 区生物学
小类|3 区生化与分子生物学
第一作者:
第一作者机构:[1]Department of Traditional Chinese Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, 510280, Guangdong, China.
共同第一作者:
通讯作者:
通讯机构:[2]Department of VIP Region, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, China.[*1]Department of VIP Region, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, Guangdong, China
推荐引用方式(GB/T 7714):
Shi Lin,Kan Jun,Zhuo Lin,et al.Bioinformatics identification of miR-514b-5p promotes NSCLC progression and induces PI3K/AKT and p38 pathways by targeting small glutamine-rich tetratricopeptide repeat-containing protein beta[J].FEBS JOURNAL.2023,290(4):1134-1150.doi:10.1111/febs.16639.
APA:
Shi Lin,Kan Jun,Zhuo Lin,Wang Siyun,Chen Shaobing...&Ke Bin.(2023).Bioinformatics identification of miR-514b-5p promotes NSCLC progression and induces PI3K/AKT and p38 pathways by targeting small glutamine-rich tetratricopeptide repeat-containing protein beta.FEBS JOURNAL,290,(4)
MLA:
Shi Lin,et al."Bioinformatics identification of miR-514b-5p promotes NSCLC progression and induces PI3K/AKT and p38 pathways by targeting small glutamine-rich tetratricopeptide repeat-containing protein beta".FEBS JOURNAL 290..4(2023):1134-1150